|Membership of professional bodies:
2011: Fellow Royal College of Physicians
2007: UK and Ireland Neuroendocrine Tumour Society
2006: European Society for Endocrinology
2002: American Endocrine Society
2000: Society for Endocrinology
||I am Clinical Lead for Endocrinology with clinical specialist
interests in neuroendocrinology, endocrine genetic syndromes,
endocrine late effects of childhood cancer, antenatal endocrinology
and endocrinology in a critical care setting. I chair the regional
UHBristol Neuroendocrine MDT. In addition, I have University of
Bristol funded academic sessions and have secured both funding and
ethical approval for my initial programme of research to study the
HPA axis in various critical illness scenarios. I am grateful to
the David Telling Charitable Trust, Above & Beyond Charities
and the Society for Endocrinology (Early Career Grant) for their
financial support. I am also a successful co-applicant on a three
year MRC grant (PI Professor Stafford Lightman) to deliver
research studies in patients with Addison's disease and Congenital
Adrenal Hyperplasia. I contribute to the specialty at a national
level through a variety of roles including being a PACES examiner,
being an elected member of the Editorial Board of Clinical
Endocrinology, being the elected Media Representative of the Public
Engagement Committee of the Society for Endocrinology and since
2010 co-organising two very successful annual regional endocrine
meetings - the SW Endocrine Symposium and the BBCO (Bristol,
Birmingham, Cardiff and Oxford) Neuroendocrine Meeting.
|Web links to any published articles:
Manuscripts and textbook chapters (Excluding abstracts) since
- Bradley KJ. External Senior Reviewer for Chapters on
Neuroendocrine Tumours and Genetic Endocrine Syndromes. Oxford
Handbook of Endocrinology and Diabetes. Oxford University Press.
Third Edition. In Press
- Raghavan R, Taylor PN, Bhake R, VaidyaB, Martino E, Bartalena
L, Dayan CM,Bradley KJ.Amiodarone Induced Thyrotoxicosis, an
overview of UK management. Clinical Endocrinology 2012. 77(6):
- Raghavan R &Bradley KJ. Hypopituitarism. GP Newspaper
- Bradley KJ. Chapters on Neuroendocrine Tumours and Genetic
Endocrine Syndromes. Oxford Handbook of Endocrinology and Diabetes.
Oxford University Press. Second Edition. Edited by JAH Wass and HE
- Bradley KJ, Bowl MR, Williams SE, Ahmad BN, Partridge C,
Patmanidi AL, Kennedy AM, Loh NY & Thakker RV.
PARAFIBROMIN is a nuclear protein with a functional monopartite
NLS. Oncogene 2006. 26: 1213-1221.
- Bradley KJ& Thakker RV. The Hyperparathyroidism-Jaw Tumour
Syndrome. Clinical Cases in Bone & Mineral Metabolism 2006.
- Bradley KJ.Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter
C, Besser GM, da Conceição Pereira M, Davie MWJ, Dudley N,
Leite V, Sadler G, Seller A & Thakker RV. PARAFIBROMIN
mutations in hereditary hyperparathyroidism syndromes and
parathyroid tumours. Clinical Endocrinology (Oxf) 2006: 64(3):
- Bradley KJ.Pituitary Incidentalomas. Clinical Endocrine
Oncology. Blackwell Publishing. Second Edition 2006. Edited by JAH
Wass and I Hay.
- Bradley KJ, Cavaco BM, Bowl MR, Harding B, Young A &
Thakker RV. Utilisation of a cryptic non-canonical donor splice
site of the gene encoding PARAFIBROMIN is associated with familial
isolated hyperparathyroidism. Journal of Medical Genetics 2005: 42:
- Bradley KJ, Hobbs MR, Buley ID, Carpten JD, Cavaco BM, Fares
JE, Laidler P, Manek S, Robbins CM, Salti IS, Thompson NW, Jackson
C. & Thakker RV. Uterine tumours are a phenotypic manifestation
of the hyperparathyroidism-jaw tumour syndrome. Journal of Internal
Medicine 2005: 257(1): 18-26.